SOURCE: IO NewsWire

September 20, 2011 13:19 ET

Cannabis Science Appoints New Investor Relations Manager

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire

NEW YORK, NY--(Marketwire - Sep 20, 2011) - Cannabis Science, Inc. (OTCBB: CBIS) a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that Robert Kane, formerly of Stifel Nicolaus (NYSE: SF), has been retained by Cannabis Science in the capacity of Investor Relations Management.

Medical Marijuana as reported in a CNBC article (www.bit.ly/pQSApf) is estimated to be anywhere from $10 billion to $120 billion annually and expected to grow. In a See Change Strategy LLC (www.bit.ly/oF0sTI) report it is highlighted the fact that in 15 years, 15 states have adopted laws permitting some form of marijuana consumption. This leaves an extraordinary amount of room for the industry to grow as more states adopt policies allowing Cannabis use.

Other active stocks are Progenics Pharmaceuticals (NASDAQ: PGNX) and Acorda Therapeutics, Inc (NASDAQ: ACOR).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information